Singapore markets closed
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,460.44 -8.86 (-0.16%) Dow
39,056.14 -56.02 (-0.14%) Nasdaq
17,738.86 +21.21 (+0.12%) Bitcoin USD
61,732.49 -30.26 (-0.05%) CMC Crypto 200
1,278.77 -5.02 (-0.39%)
ITCI Nov 2024 100.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 01:30PM EDT. Market open.
| Previous close | 1.9500 |
| Open | 1.9500 |
| Bid | 0.2000 |
| Ask | 3.1000 |
| Strike | 100.00 |
| Expiry date | 2024-11-15 |
| Day's range | 1.9500 - 1.9500 |
| Contract range | N/A |
| Volume | |
| Open interest | 500 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.